Exosomal miR‐181d‐5p Derived from Rapamycin‐Conditioned MDSC Alleviated Allograft Rejection by Targeting KLF6
Source abstract
Abstract
Abstract Immune rejection and side effects of long‐term administration of immunosuppressants are the two major obstacles to allograft acceptance and tolerance. The immunosuppressive extracellular vesicles (EVs)‐based approach has been proven to be effective in treating autoimmune/inflammatory disorders. Herein, the anti‐rejection advantage of exosomes (Rapa‐Exo) from rapamycin‐conditioned myeloid‐derived suppressor cells (MDSCs) over exosomes (Exo‐Nor) from the untreated MDSCs is shown. The exosomal small RNA sequencing and loss‐of‐function assays reveal that the anti‐rejection effect of Rapa‐Exo functionally relies on miR‐181d‐5p. Through target prediction and double‐luciferase reporter assay, Kruppel‐like factor (KLF) 6 is identified as a direct target of miR‐181d‐5p. Finally, KLF6 knockdown markedly resolves inflammation and prolongs the survival of corneal allografts. Taken together, these findings support that Rapa‐Exo executes an anti‐rejection effect, highlighting the immunosuppressive EVs‐based treatment as a promising approach in organ transplantation.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Extracellular vesicles in disease · Reproductive System and Pregnancy · MicroRNA in disease regulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory Cultivation Base Shandong Provincial Key Laboratory of Ophthalmology Eye Institute of Shandong First Medical University Qingdao 266071 China
Eye Hospital of Shandong First Medical University (Shandong Eye Hospital) Jinan 250117 China
School of Ophthalmology Shandong First Medical University & Shandong Academy of Medical Science Jinan 250117 China
Funding
National Natural Science Foundation of China · Natural Science Foundation of Shandong Province · Taishan Scholar Foundation of Shandong Province
References (70)
Show source-provided references
1. 10.1056/NEJMra201453010.1056/NEJMra2014530 ↗
2. 10.1038/nrg.2017.1210.1038/nrg.2017.12 ↗
3. 10.1111/ajt.1700110.1111/ajt.17001 ↗
4. 10.1038/nrneph.2010.10210.1038/nrneph.2010.102 ↗
5. 10.1111/ajt.1232410.1111/ajt.12324 ↗
6. 10.1136/bmj.m373410.1136/bmj.m3734 ↗
7. 10.1073/pnas.162074611410.1073/pnas.1620746114 ↗
8. 10.1111/j.1600-6143.2012.04269.x10.1111/j.1600-6143.2012.04269.x ↗
9. 10.1016/j.trim.2012.05.00110.1016/j.trim.2012.05.001 ↗
10. 10.1016/S0140-6736(17)31283-710.1016/S0140-6736(17)31283-7 ↗
11. 10.1038/s41580-020-0251-y10.1038/s41580-020-0251-y ↗
12. 10.1016/j.cell.2016.01.04310.1016/j.cell.2016.01.043 ↗
13. 10.1126/science.aau697710.1126/science.aau6977 ↗
14. 10.1016/j.cell.2023.03.01010.1016/j.cell.2023.03.010 ↗
15. 10.1038/s41565-021-00931-210.1038/s41565-021-00931-2 ↗
16. 10.1038/s41573-021-00139-y10.1038/s41573-021-00139-y ↗
17. 10.1038/s41571-018-0036-910.1038/s41571-018-0036-9 ↗
18. 10.1038/s41573-022-00410-w10.1038/s41573-022-00410-w ↗
19. 10.1038/s41569-020-0389-510.1038/s41569-020-0389-5 ↗
20. Robson A. · Nat. Rev. Cardiol. · 2020 · 17 · 758
21. 10.1016/j.biomaterials.2021.12089410.1016/j.biomaterials.2021.120894 ↗
22. 10.1021/nn402232g10.1021/nn402232g ↗
23. 10.1126/scitranslmed.aay131810.1126/scitranslmed.aay1318 ↗
24. 10.1021/acsnano.1c0062810.1021/acsnano.1c00628 ↗
25. 10.1021/acsnano.9b0189210.1021/acsnano.9b01892 ↗
26. 10.1016/j.biomaterials.2021.12116910.1016/j.biomaterials.2021.121169 ↗
27. 10.1002/jev2.1208810.1002/jev2.12088 ↗
28. 10.1002/advs.20190051310.1002/advs.201900513 ↗
29. 10.1016/j.biomaterials.2021.12132010.1016/j.biomaterials.2021.121320 ↗
30. 10.1016/j.immuni.2014.05.01910.1016/j.immuni.2014.05.019 ↗
31. 10.1002/eji.20124290910.1002/eji.201242909 ↗
32. 10.1016/j.apsb.2022.08.02010.1016/j.apsb.2022.08.020 ↗
33. 10.1017/erm.2021.3310.1017/erm.2021.33 ↗
34. Zhu D. L. · Circ. Res. · 2022 · 131
35. 10.1038/s41581-018-0023-510.1038/s41581-018-0023-5 ↗
36. 10.1002/adma.20210847610.1002/adma.202108476 ↗
37. 10.1126/sciadv.aaz698010.1126/sciadv.aaz6980 ↗
38. 10.1016/j.celrep.2019.12.08110.1016/j.celrep.2019.12.081 ↗
39. 10.1126/scitranslmed.aac560810.1126/scitranslmed.aac5608 ↗
40. 10.1126/sciadv.abe008310.1126/sciadv.abe0083 ↗
41. 10.1126/scitranslmed.aba059910.1126/scitranslmed.aba0599 ↗
42. 10.1021/acsnano.9b0100410.1021/acsnano.9b01004 ↗
43. 10.1002/advs.20210263410.1002/advs.202102634 ↗
44. 10.1111/acel.1346110.1111/acel.13461 ↗
45. 10.1002/jev2.1223710.1002/jev2.12237 ↗
46. 10.1016/j.jconrel.2016.07.04410.1016/j.jconrel.2016.07.044 ↗
47. 10.3389/fimmu.2018.0228310.3389/fimmu.2018.02283 ↗
48. 10.3390/jfb1401004910.3390/jfb14010049 ↗
49. 10.3389/fimmu.2020.58850010.3389/fimmu.2020.588500 ↗
50. 10.1016/j.bbadis.2019.16554010.1016/j.bbadis.2019.165540 ↗
51. 10.18632/oncotarget.732410.18632/oncotarget.7324 ↗
52. 10.3389/fimmu.2018.0127910.3389/fimmu.2018.01279 ↗
53. 10.1016/j.cellimm.2020.10425810.1016/j.cellimm.2020.104258 ↗
54. 10.1021/acs.jproteome.7b0064610.1021/acs.jproteome.7b00646 ↗
55. 10.3389/fimmu.2020.0105110.3389/fimmu.2020.01051 ↗
56. 10.1038/cr.2011.19610.1038/cr.2011.196 ↗
57. 10.1038/s41598-017-08617-310.1038/s41598-017-08617-3 ↗
58. 10.1186/s13578-022-00808-410.1186/s13578-022-00808-4 ↗
59. 10.3389/fimmu.2022.87009410.3389/fimmu.2022.870094 ↗
60. Li J. · Mediators Inflamm. · 2022 · 2022
61. Hua Q. · Toxicol. Sci. · 2021 · 179 · 70
62. 10.1038/s41590-021-00968-410.1038/s41590-021-00968-4 ↗
63. 10.1096/fj.201902221R10.1096/fj.201902221R ↗
64. 10.1038/mi.2016.110.1038/mi.2016.1 ↗
65. 10.1074/jbc.M113.53583110.1074/jbc.M113.535831 ↗
66. 10.3389/fphys.2020.0051010.3389/fphys.2020.00510 ↗
67. 10.1080/20013078.2018.156080910.1080/20013078.2018.1560809 ↗
68. 10.1111/ajt.1696810.1111/ajt.16968 ↗
69. 10.1111/ajt.1607110.1111/ajt.16071 ↗
70. 10.1126/sciadv.abj961710.1126/sciadv.abj9617 ↗